Overall Survival Data from a 3-Arm, Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, Combined with Nab-Paclitaxel in Patients with Recurrent Platinum-Resistant Ovarian Cancer.
Gynecologic Oncology(2024)
关键词
Cortisol Response,Glucocorticoid Replacement
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要